APLT

Applied Therapeutics, Inc. [APLT] Stock Forecast

Q: What is Applied Therapeutics, Inc. stock symbol ?

Applied Therapeutics, Inc. is a US stock, located in New york of Ny and trading under the symbol APLT

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

APLT Stock Summary

EPS has been increasing for the past 3 years (Yearly statements)

The Moving Average Convergence Divergence (MACD) for APLT recently turned positive (within last 10 days).

APLT has more than 12 years of cash runway (153 months)

An RSI reading of 70 or higher indicates an overbought or overvalued condition.

In the last year, shareholders have seen their holdings diluted. Dilution over past year is 84.62%

EPS has been decreasing for the past 3 quarters (Quarter statements)

Currently unprofitable, and not expected to turn profitable in the coming year

Top 10 Correlated ETFs

APLT

Top 10 Correlated Stocks

APLT

In the News

03:36 10 Dec 2023 APLT

3 Penny Stocks To Buy According To Insiders In December

Penny stocks – the cheap stocks trading under $5 per share, offer investors massive upside potential alongside higher risk. Since even incremental price moves translate into huge percentage gains in the stock market, timing entries right can set you up for explosive profits.

07:00 10 Dec 2023 APLT

Applied Therapeutics to Present Baseline Data from Phase 3 ARISE-HF Study Evaluating AT-001 at the 2023 EASD Annual Meeting

The ongoing ARISE-HF Phase 3 global clinical trial is evaluating the efficacy of AT-001 (caficrestat) on cardiac functional capacity in patients with diabetic cardiomyopathy (DbCM) Baseline data from ARISE-HF shows patients with DbCM exhibit reduced cardiac functional capacity resulting in decreased physical activity NEW YORK, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it will participate in a Symposium presentation, entitled Diabetic Cardiomyopathy (DbCM): a severe complication of diabetes, at the 59th European Association for the Study of Diabetes (EASD) Annual Meeting to take place October 2-6, 2023 in Hamburg, Germany and online.

04:28 10 Dec 2023 APLT

Applied Therapeutics: Buy For Upcoming Pre-NDA Meeting (I Expect A Positive Outcome)

Applied Therapeutics is a micro-cap with low cash balance, but has major upcoming catalysts (pre-NDA meeting for galactosemia and phase 3 results in diabetic cardiomyopathy) and a huge upside potential. Despite missing the primary endpoint in galactosemia ph3 trial, APLT still plans for NDA submission. The pre-NDA meeting with the FDA this summer will be a big catalyst if positive. I expect a positive outcome from the meeting considering consistent and meaningful clinical benefit in multiple endpoints, orphan and fast-track designation, no alternative treatments, and the significant burden for affected patients.

07:00 10 Dec 2023 APLT

Applied Therapeutics to Present Baseline Data on the Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at the 2023 Annual Meeting of the American Diabetes Association

NEW YORK, June 22, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced multiple presentations on AT-001 (caficrestat) and the ARISE-HF Phase 3 study in Diabetic Cardiomyopathy at the 2023 Annual Meeting of the American Diabetes Association to take place June 23 - 26 in San Diego, California.

02:24 10 Dec 2023 APLT

7 Hot Growth Stocks Poised to Triple in 2023

Any investor seeking growth stocks that are poised to triple in 2023 will need a strong appetite for risk. That much is very clear.

11:12 10 Dec 2023 APLT

4 Top Penny Stocks To Buy According To Analysts, Targets Up To 695%

Analysts say these could be penny stocks to buy. Do you agree with their outlook?

11:28 10 Dec 2023 APLT

3 Penny Stocks To Buy According To Analysts, Targets Up To 1,029%

Analysts say these are penny stocks to buy but do you agree? The post 3 Penny Stocks To Buy According To Analysts, Targets Up To 1,029% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

07:00 10 Dec 2023 APLT

Applied Therapeutics to Present at the Cowen 43rd Annual Health Care Conference

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will participate in a Neuromuscular & Bone Panel at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, 2023 at 2:10 p.m. ET in Boston.

07:00 10 Dec 2023 APLT

Applied Therapeutics to Present at the SVB Securities Global Biopharma Conference

NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present virtually at the SVB Securities Global Biopharma Conference on Thursday, February 16, 2023 at 2:20 p.m. ET.

09:14 10 Dec 2023 APLT

7 Top Penny Stocks To Watch With Big News This Week

Hot penny stocks to watch with news this week. The post 7 Top Penny Stocks To Watch With Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

APLT Financial details

Company Rating

Buy

Market Cap

240.18M

Income

-87.18M

Revenue

10.66M

Book val./share

-0.12

Cash/share

0.41

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

09 Nov 2023

P/E

-3.23

Forward P/E

-3.05

PEG

0.45

P/S

22.53

P/B

-25.53

P/C

7.59

P/FCF

-4.44

Quick Ratio

0.68

Current Ratio

0.8

Debt / Equity

-0.12

LT Debt / Equity

-0

EPS (TTM)

-1.16

EPS next Y

-1.02

EPS next Q

-0.26

EPS this Y

-47.19%

EPS next Y

-12.22%

EPS next 5Y

-24.39%

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

27.03%

SMA20

4.37%

SMA50

-6.27%

SMA100

70.71%

Inst Own

43.47%

Inst Trans

0.78%

ROA

-193%

ROE

2266%

ROC

6.06%

Gross Margin

100%

Oper. Margin

-586%

Profit Margin

-818%

Payout

Shs Outstand

77.23M

Shs Float

52.28M

Target Price

52W Range

0.7-3.365

52W High

52W Low

RSI

72.45

Rel Volume

3.66

Avg Volume

1.04M

Volume

3.81M

Perf Week

53.96%

Perf Month

9.89%

Perf Quarter

111.56%

Perf Half Y

114.48%

Beta

1.427

Volatility

0.3%, 0.28%

Prev Close

16.48%

Price

3.11

Change

24.9%

APLT Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0	0
Net income per share	-1.8	-3.54	-4.23	-4.09	-2.16
Operating cash flow per share	-1.22	-2.83	-3.56	-3.54	-2.06
Free cash flow per share	-1.22	-2.83	-3.56	-3.54	-2.06
Cash per share	2.05	3.03	4.41	3.16	0.81
Book value per share	1.73	2.54	3.73	2.44	0.11
Tangible book value per share	1.73	2.54	3.73	2.44	0.11
Share holders equity per share	1.73	2.54	3.73	2.44	0.11
Interest debt per share	0	0.17	0.1	0.07	0.01
Market cap	86.13M	350.04M	483.48M	229.1M	28.75M
Enterprise value	67.39M	333.22M	427.75M	176.55M	12.98M
P/E ratio	-5.21	-7.71	-5.2	-2.19	-0.35
Price to sales ratio	0	0	0	0	0
POCF ratio	-7.7	-9.64	-6.18	-2.53	-0.37
PFCF ratio	-7.7	-9.64	-6.18	-2.53	-0.37
P/B Ratio	5.45	10.73	5.9	3.66	7.08
PTB ratio	5.45	10.73	5.9	3.66	7.08
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-5.07	-7.31	-4.53	-1.67	-0.16
EV to operating cash flow	-6.03	-9.18	-5.47	-1.95	-0.17
EV to free cash flow	-6.03	-9.18	-5.47	-1.95	-0.17
Earnings yield	-0.19	-0.13	-0.19	-0.46	-2.84
Free cash flow yield	-0.13	-0.1	-0.16	-0.4	-2.72
Debt to equity	0	0.06	0.02	0.02	0.22
Debt to assets	0	0.04	0.02	0.01	0.02
Net debt to EBITDA	1.41	0.37	0.59	0.5	0.19
Current ratio	4.57	3.27	4.83	3.34	1.12
Interest coverage	0	-490.13	-168.99	-190.3	187.67
Income quality	0.68	0.8	0.83	0.86	0.95
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	0	0	0	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	8.37	14.22	18.85	14.99	2.28
ROIC	-1.11	-1.24	-1.09	-1.6	-14.06
Return on tangible assets	-0.82	-0.94	-0.89	-1.16	-2.13
Graham Net	1.56	1.8	3.39	2.09	-0.1
Working capital	15.82M	32.06M	81.36M	61.93M	3.88M
Tangible asset value	15.82M	32.61M	81.94M	62.54M	4.06M
Net current asset value	15.82M	30.37M	80.03M	61.04M	3.01M
Invested capital	0	0.06	0.02	0.02	0.22
Average receivables	0	0	252.5K	515K	400K
Average payables	1.86M	5.9M	4.72M	5.05M	7M
Average inventory	0	0	-252.5K	-515K	-400K
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-1.04	-1.39	-1.14	-1.67	-20.12
Capex per share	0	0	0	0	0

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric	2022-09-30	2022-12-31	2023-03-31	2023-06-30	2023-09-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0.19	0	0
Net income per share	-0.39	-0.15	-0.17	-0.37	-0.47
Operating cash flow per share	-0.4	-0.42	-0.12	-0.21	-0.16
Free cash flow per share	-0.4	-0.42	-0.12	-0.21	-0.16
Cash per share	0.99	0.81	0.41	0.45	0.41
Book value per share	0.2	0.11	-0.07	-0.05	-0.12
Tangible book value per share	0.2	0.11	-0.07	-0.05	-0.12
Share holders equity per share	0.2	0.11	-0.07	-0.05	-0.12
Interest debt per share	0.05	0.05	0	0.02	0.01
Market cap	44.64M	28.75M	45.71M	101.17M	225.77M
Enterprise value	6.82M	14.07M	23.57M	67.45M	189.62M
P/E ratio	-0.59	-1.24	-1.21	-0.86	-1.33
Price to sales ratio	0	0	4.29	0	0
POCF ratio	-2.3	-1.81	-6.54	-6.15	-15.33
PFCF ratio	-2.3	-1.81	-6.54	-6.15	-15.33
P/B Ratio	4.64	7.08	-11.23	-23.34	-20.44
PTB ratio	4.64	7.08	-11.23	-23.34	-20.44
EV to sales	0	0	2.21	0	0
Enterprise value over EBITDA	-0.35	-0.61	-2.08	-15.85	-12.24
EV to operating cash flow	-0.35	-0.89	-3.37	-4.1	-12.88
EV to free cash flow	-0.35	-0.89	-3.37	-4.1	-12.88
Earnings yield	-0.42	-0.2	-0.21	-0.29	-0.19
Free cash flow yield	-0.43	-0.55	-0.15	-0.16	-0.07
Debt to equity	0.27	0.49	-0.19	-0.44	-0.12
Debt to assets	0.05	0.05	0.03	0.04	0.03
Net debt to EBITDA	1.96	0.64	1.95	7.92	2.33
Current ratio	1.19	1.12	0.87	0.91	0.8
Interest coverage	75.91	101.45	15.06	0	0
Income quality	1.02	1.1	0.69	0.56	0.35
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0.52	0	0
Research and developement to revenue	0	0	1.49	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	0	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	0	0	0	0
Stock based compensation to revenue	0	0	0.19	0	0
Graham number	1.33	0.61	0.52	0.68	1.13
ROIC	-1.44	-1.1	4	13.68	1.68
Return on tangible assets	-0.33	-0.15	-0.31	-0.68	-0.94
Graham Net	0.01	-0.02	-0.2	-0.11	-0.18
Working capital	9M	3.88M	-4.19M	-4.37M	-11.02M
Tangible asset value	9.63M	4.06M	-4.07M	-4.33M	-11.04M
Net current asset value	8.46M	3.01M	-5.01M	-5.16M	-11.75M
Invested capital	0.27	0.49	-0.19	-0.44	-0.12
Average receivables	282K	275.5K	280K	285K	285K
Average payables	7.83M	5.75M	5.04M	5.12M	5.35M
Average inventory	-138K	2.52M	2.52M	3.05M	5.67M
Days sales outstanding	0	0	2.41	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	37.4	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-1.95	-1.43	2.31	6.82	3.84
Capex per share	0	0	0	0	0

APLT Frequently Asked Questions

What is Applied Therapeutics, Inc. stock symbol ?

Applied Therapeutics, Inc. is a US stock , located in New york of Ny and trading under the symbol APLT

What is Applied Therapeutics, Inc. stock quote today ?

Applied Therapeutics, Inc. stock price is $3.11 today.

Is Applied Therapeutics, Inc. stock public?

Yes, Applied Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 1.04M
Market Capitalization 240.18M
Employee 22
CEO Dr. Shoshana Shendelman Ph.D.
Headquarters New York,NY,US
IPO Date 2019-05-14
Website https://www.appliedtherapeutics.com

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.